In a significant development, the U.S. Supreme Court recently declined to hear an appeal, effectively ruling that Monsanto, now owned by Bayer, cannot be held liable under state laws for failing to warn consumers about the alleged cancer risks of its popular weedkiller, Roundup, on its product label. This decision, emerging from ongoing litigation across the United States, reinforces the principle that federal labeling regulations can preempt state-level requirements, potentially limiting the avenues for plaintiffs seeking compensation for non-Hodgkin lymphoma claims.
The Enduring Roundup Controversy
Roundup, a ubiquitous herbicide developed by Monsanto, has been a cornerstone of agricultural and residential weed control for decades. Its active ingredient, glyphosate, has been at the center of a protracted scientific and legal debate regarding its potential link to cancer, specifically non-Hodgkin lymphoma. Millions of pounds of glyphosate are applied annually in the U.S., making its safety profile a matter of widespread public health concern.
For years, Monsanto and its acquirer, Bayer, have faced thousands of lawsuits from individuals alleging that exposure to Roundup caused their cancer and that the company failed to adequately warn them of these risks. These cases have resulted in mixed verdicts, with some juries awarding billions in damages to plaintiffs, while others have sided with the company. The core of many of these claims revolved around the argument that Monsanto had a duty under state law to provide more explicit warnings on its product labels.
Federal Preemption Takes Center Stage
The Supreme Court’s decision hinges on the legal doctrine of federal preemption, specifically concerning the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). FIFRA is the federal law that governs the registration, labeling, and sale of pesticides in the United States, granting the Environmental Protection Agency (EPA) the authority to approve pesticide labels. Monsanto and Bayer have consistently argued that because the EPA has approved Roundup’s label and has maintained that glyphosate is not likely to be carcinogenic, state laws requiring additional warnings are preempted.
The EPA has consistently held that glyphosate is “not likely to be carcinogenic to humans,” a stance it reaffirmed in 2020. This federal position directly contrasts with the 2015 classification by the International Agency for Research on Cancer (IARC), a World Health Organization agency, which concluded that glyphosate is “probably carcinogenic to humans.” This scientific divergence has fueled much of the legal and public health debate.
Implications for Ongoing Litigation and Industry
The Supreme Court’s refusal to hear the appeal, effectively upholding lower court rulings in favor of Monsanto, significantly narrows the legal pathway for many of the estimated tens of thousands of pending Roundup lawsuits. Specifically, claims based solely on a “failure-to-warn” theory under state law are now largely barred. This represents a substantial victory for Bayer, which has already spent billions of dollars attempting to resolve the Roundup litigation.
Legal experts suggest this ruling does not completely absolve Bayer of all liability. Plaintiffs may still pursue claims based on other legal theories, such as design defect or manufacturing defect, though these are often more challenging to prove. However, the preemption of failure-to-warn claims removes a significant portion of the company’s legal exposure related to glyphosate.
For the agricultural and chemical industries, this decision provides a clearer framework regarding product liability for federally regulated substances. It reinforces the power of federal agencies like the EPA in dictating product labeling and shields manufacturers from potentially conflicting state-level warning requirements once a federal label is approved. Consumer advocacy groups, however, express concern that the ruling may limit consumers’ ability to seek justice and could undermine states’ rights to protect their citizens from potentially harmful products.
What to Watch Next
Moving forward, attention will likely shift to the remaining categories of Roundup lawsuits and how plaintiffs’ attorneys adapt their strategies in light of this Supreme Court decision. There may be increased legislative pressure on Congress to amend FIFRA to allow state-level warning claims, or to re-evaluate the EPA’s authority and processes for pesticide approval. The scientific debate over glyphosate’s safety is also far from over, with ongoing research and public discourse continuing to shape perceptions and potentially influence future regulatory actions. The financial implications for Bayer, while eased by this ruling, will also continue to be monitored as the company navigates the remaining legal challenges and public relations hurdles.
